Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription


2 AJR Am J Roentgenol
2 Am J Pathol
2 Ann Oncol
10 Ann Surg Oncol
3 BMC Cancer
1 Br J Cancer
2 Breast Cancer
3 Breast Cancer (Dove Med Press)
2 Breast Cancer Res
3 Breast Cancer Res Treat
1 Carcinogenesis
2 Clin Breast Cancer
2 Clin Cancer Res
3 Eur Radiol
1 Exp Cell Res
1 Histopathology
1 Int J Cancer
1 Int J Oncol
2 J Clin Oncol
1 J Natl Cancer Inst
2 J Pathol
1 Mod Pathol
2 NPJ Breast Cancer
1 Oncogene
1 Oncol Rep
1 Oncology
4 PLoS One
1 Radiother Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. BITENCOURT AGV, Barbosa PNVP, Chojniak R
    Expanding Biopsy Options for Suspicious Breast Lesions: CT-Guided Biopsy Using a 3D-Printed Device.
    AJR Am J Roentgenol. 2023 Jul 5:1-2. doi: 10.2214/AJR.23.29421.

  2. WEAVER OO, Kornecki A, Yang WT
    Reply to: "Expanding Biopsy Options for Suspicious Breast Lesions: CT-Guided Biopsy Using a 3D-Printed Device".
    AJR Am J Roentgenol. 2023 Jul 5:2. doi: 10.2214/AJR.23.29476.

    Am J Pathol

  3. SAATCHI Y, Schanen P, Cheung RA, Petty HR, et al
    Computer Vision Identifies Recurrent and Nonrecurrent Ductal Carcinoma in Situ Lesions with Special Emphasis on African-American Women.
    Am J Pathol. 2023;193:1195-1207.
    PubMed         Abstract available

  4. WU K, Li W, Liu H, Niu C, et al
    Metabolome Sequencing Reveals that Protein Arginine-N-Methyltransferase 1 Promotes the Progression of Invasive Micropapillary Carcinoma of the Breast and Predicts a Poor Prognosis.
    Am J Pathol. 2023;193:1267-1283.
    PubMed         Abstract available

    Ann Oncol

  5. PARSONS HA, Blewett T, Chu X, Sridhar S, et al
    Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Ann Oncol. 2023 Aug 17:S0923-7534(23)00801-3. doi: 10.1016/j.annonc.2023.
    PubMed         Abstract available

  6. JHAVERI K, Eli LD, Wildiers H, Hurvitz SA, et al
    Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
    Ann Oncol. 2023 Aug 17:S0923-7534(23)00800-1. doi: 10.1016/j.annonc.2023.
    PubMed         Abstract available

    Ann Surg Oncol

  7. LUCCI A, Kim LS, Golshan M, King TA, et al
    Great Debate: The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer.
    Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14134.

  8. XU C, Pfob A, Mehrara BJ, Yin P, et al
    ASO Visual Abstract: Enhanced Surgical Decision-Making Tools in Breast Cancer-Predicting 2-Year Postoperative Physical, Sexual, and Psychosocial Well-Being Following Mastectomy and Breast Reconstruction (INSPiRED 004).
    Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14095.

  9. AL-HILLI Z, Noss R, Dickard J, Wei W, et al
    ASO Visual Abstract: A Randomized Trial Comparing the Effectiveness of Pre-test Genetic Counseling Using an Artificial Intelligence Automated Chatbot and Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer.
    Ann Surg Oncol. 2023 Aug 21. doi: 10.1245/s10434-023-13989.

  10. ZAVERI S, Everidge S, FitzSullivan E, Hwang R, et al
    ASO Visual Abstract: Extremely Low Incidence of Local-Regional Recurrences Observed among T1-2N1 (one or two Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy without Completion Axillary Node Dissection.
    Ann Surg Oncol. 2023 Aug 23. doi: 10.1245/s10434-023-14088.

  11. JEFFERS EJ, Wagner JL, Kilgore LJ
    ASO Author Reflections: Breast Cancer-Related Lymphedema (BCRL) Surveillance Recommendations with Bioimpedance Spectroscopy.
    Ann Surg Oncol. 2023 Aug 23. doi: 10.1245/s10434-023-14099.

  12. BARKER VR, Naffouje SA, Mallory MA, Hoover SA, et al
    Surgical Management of the Axilla in HR+/HER2- Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database.
    Ann Surg Oncol. 2023 Aug 23. doi: 10.1245/s10434-023-14029.
    PubMed         Abstract available

  13. ADESOYE T, Lucci A
    ASO Author Reflections: Low Rates of Local-Regional Recurrence in Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.
    Ann Surg Oncol. 2023 Aug 23. doi: 10.1245/s10434-023-14159.

  14. FERRUCCI M, Milardi F, Passeri D, Mpungu LF, et al
    Intraoperative Ultrasound-Guided Conserving Surgery for Breast Cancer: No More Time for Blind Surgery.
    Ann Surg Oncol. 2023 Aug 22. doi: 10.1245/s10434-023-13900.
    PubMed         Abstract available

  15. HSIEH YC, Guo KW, Wang MW, Su SP, et al
    A Novel Injection Protocol Using Voluven(R)-Assisted Indocyanine Green with Improved Near-Infrared Fluorescence Guidance in Breast Cancer Sentinel Lymph Node Mapping-A Translational Study.
    Ann Surg Oncol. 2023 Aug 21. doi: 10.1245/s10434-023-14129.
    PubMed         Abstract available

  16. FASOLA CE, Sharp HJ, Clavin NW, Sha W, et al
    Effect of Delayed Oncoplastic Reduction Mammoplasty on Radiation Treatment Delay Following Breast-Conserving Surgery for Breast Cancer.
    Ann Surg Oncol. 2023 Aug 21. doi: 10.1245/s10434-023-14177.
    PubMed         Abstract available

    BMC Cancer

  17. WU Q, Tao X, Luo Y, Zheng S, et al
    A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer.
    BMC Cancer. 2023;23:776.
    PubMed         Abstract available

  18. CORTES J, Haiderali A, Huang M, Pan W, et al
    Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2023;23:792.
    PubMed         Abstract available

  19. KJELDSTED E, Ammitzboll G, Jorgensen LB, Lodin A, et al
    Neo-train: study protocol and feasibility results for a two-arm randomized controlled trial investigating the effect of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer.
    BMC Cancer. 2023;23:777.
    PubMed         Abstract available

    Br J Cancer

  20. ZHU S, Lu Y, Fei X, Shen K, et al
    Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.
    Br J Cancer. 2023 Aug 21. doi: 10.1038/s41416-023-02403.
    PubMed         Abstract available

    Breast Cancer

  21. MURATA T, Yoshida M, Shiino S, Watase C, et al
    Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.
    Breast Cancer. 2023 Aug 23. doi: 10.1007/s12282-023-01500.
    PubMed         Abstract available

  22. OHSUMI S
    Reply to "Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?".
    Breast Cancer. 2023 Aug 21. doi: 10.1007/s12282-023-01495.

    Breast Cancer (Dove Med Press)

  23. HAQUE R, Chen LH, Oestreicher N, Lalla D, et al
    Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan.
    Breast Cancer (Dove Med Press). 2023;15:637-645.
    PubMed         Abstract available

  24. ZHAN CH, Liu GJ
    Diagnostic Value of a Combined Serum alpha-Hydroxybutyrate Dehydrogenase, Carcinoembryonic Antigen and Glycoantigen 125 Test for Early-Stage Breast Cancer.
    Breast Cancer (Dove Med Press). 2023;15:617-623.
    PubMed         Abstract available

  25. SHIRMAN Y, Lubovsky S, Shai A
    HER2-Low Breast Cancer: Current Landscape and Future Prospects.
    Breast Cancer (Dove Med Press). 2023;15:605-616.
    PubMed         Abstract available

    Breast Cancer Res

  26. LIU S, Chen W, Hu H, Zhang T, et al
    Correction: Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2023;25:98.

  27. CASTILLO-CASTREJON M, Sankofi BM, Murguia SJ, Udeme AA, et al
    FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
    Breast Cancer Res. 2023;25:99.
    PubMed         Abstract available

    Breast Cancer Res Treat

  28. KAIYIN M, Lingling T, Leilei T, Wenjia L, et al
    Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2023 Aug 24. doi: 10.1007/s10549-023-07034.
    PubMed         Abstract available

  29. ISIKLAR AD, Aliyeva L, Yesilyurt A, Soyder A, et al
    Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Breast Cancer Res Treat. 2023 Aug 24. doi: 10.1007/s10549-023-07074.
    PubMed         Abstract available

  30. BAO T, Zhi WI, Baser RE, Li QS, et al
    Electro-acupuncture versus battle field auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: subgroup analysis of a randomized clinical trial.
    Breast Cancer Res Treat. 2023 Aug 24. doi: 10.1007/s10549-023-07072.
    PubMed         Abstract available


  31. LIU B, Fu X, Du Y, Feng Z, et al
    Pan-cancer analysis of G6PD carcinogenesis in human tumors.
    Carcinogenesis. 2023;44:525-534.
    PubMed         Abstract available

    Clin Breast Cancer

  32. ALDRICH J, Canning M, Bhave M
    Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy.
    Clin Breast Cancer. 2023 Aug 5:S1526-8209(23)00208.
    PubMed         Abstract available

  33. MANSOORI B, Kiani S, Mezajin AA, Zandi P, et al
    MicroRNA-143-5p Suppresses ER-Positive Breast Cancer Development by Targeting Oncogenic HMGA2.
    Clin Breast Cancer. 2023 Aug 3:S1526-8209(23)00207.
    PubMed         Abstract available

    Clin Cancer Res

  34. KABRAJI S, Lin NU
    Keeping it in the family: HER3 as a target in brain metastases.
    Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
    PubMed         Abstract available

  35. GAO JJ, Osgood CL, Feng Z, Bloomquist EW, et al
    FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2023 Aug 18:CCR-23-1133. doi: 10.1158/1078-0432.CCR-23-1133.
    PubMed         Abstract available

    Eur Radiol

  36. GUO Y, Xie X, Tang W, Chen S, et al
    Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer.
    Eur Radiol. 2023 Aug 19. doi: 10.1007/s00330-023-09990.
    PubMed         Abstract available

  37. QIAN N, Jiang W, Guo Y, Zhu J, et al
    Breast cancer diagnosis from contrast-enhanced mammography using multi-feature fusion neural network.
    Eur Radiol. 2023 Aug 23. doi: 10.1007/s00330-023-10170.
    PubMed         Abstract available

  38. LI Z, Ma Q, Gao Y, Qu M, et al
    Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Eur Radiol. 2023 Aug 24. doi: 10.1007/s00330-023-10155.
    PubMed         Abstract available

    Exp Cell Res

  39. WANG R, Gou Y, Tang M, Wang K, et al
    A mutator-derived prognostic eRNA signature provides insight into the pathogenesis of breast cancer.
    Exp Cell Res. 2023 Aug 21:113754. doi: 10.1016/j.yexcr.2023.113754.
    PubMed         Abstract available


  40. NIELSEN TO, Leung SCY, Riaz N, Mulligan AM, et al
    Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial.
    Histopathology. 2023 Aug 23. doi: 10.1111/his.15032.
    PubMed         Abstract available

    Int J Cancer

  41. LIGORIO F, Lobefaro R, Fuca G, Provenzano L, et al
    Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34701.
    PubMed         Abstract available

    Int J Oncol

  42. SONG J, Tang Y, Song F
    Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation.
    Int J Oncol. 2023;63:111.
    PubMed         Abstract available

    J Clin Oncol

  43. BAEK SY, Noh WC, Ahn SH, Kim HA, et al
    Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
    J Clin Oncol. 2023 Aug 22:JCO2300557. doi: 10.1200/JCO.23.00557.
    PubMed         Abstract available

  44. PUSZTAI L, Rozenblit M, Dubsky P, Bachelot T, et al
    De Novo Oligometastatic Breast Cancer.
    J Clin Oncol. 2023 Aug 22:JCO2300911. doi: 10.1200/JCO.23.00911.

    J Natl Cancer Inst

  45. LEE MK, Robson ME
    Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?
    J Natl Cancer Inst. 2023 Aug 21:djad129. doi: 10.1093.

    J Pathol

  46. PAGE DB, Broeckx G, Jahangir CA, Verbandt S, et al
    Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
    J Pathol. 2023 Aug 23. doi: 10.1002/path.6165.
    PubMed         Abstract available

  47. THAGAARD J, Broeckx G, Page DB, Jahangir CA, et al
    Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group.
    J Pathol. 2023 Aug 23. doi: 10.1002/path.6155.
    PubMed         Abstract available

    Mod Pathol

  48. RONG R, Sheng H, Jin KW, Wu F, et al
    A Deep Learning Approach for Histology-Based Nucleus Segmentation and Tumor Microenvironment Characterization.
    Mod Pathol. 2023;36:100196.
    PubMed         Abstract available

    NPJ Breast Cancer

  49. HOPCROFT L, Wigmore EM, Williamson SC, Ros S, et al
    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
    NPJ Breast Cancer. 2023;9:69.

  50. HANNA PE, Strohbehn IA, Moreno D, Harden D, et al
    Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.
    NPJ Breast Cancer. 2023;9:70.
    PubMed         Abstract available


  51. PAN JK, Lin WD, Kuo YL, Chen YC, et al
    ICAM2 initiates trans-blood-CSF barrier migration and stemness properties in leptomeningeal metastasis of triple-negative breast cancer.
    Oncogene. 2023 Jul 19. doi: 10.1038/s41388-023-02769.
    PubMed         Abstract available

    Oncol Rep

  52. LIU C, Liu Z, Li X, Tang X, et al
    [Retracted] MicroRNA‑1297 contributes to tumor growth of human breast cancer by targeting PTEN/PI3K/AKT signaling.
    Oncol Rep. 2023;50:180.
    PubMed         Abstract available


  53. LANDRY CA, Blanter J, Ru M, Fasano J, et al
    Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
    Oncology. 2023 Aug 18. doi: 10.1159/000533420.
    PubMed         Abstract available

    PLoS One

  54. FLECK JL, Hooijenga D, Phan R, Xie X, et al
    Adjuvant therapeutic strategy decision support for an elderly population with localized breast cancer: A monocentric cohort retrospective study.
    PLoS One. 2023;18:e0290566.
    PubMed         Abstract available

  55. SHI D, Liang X, Li Y, Chen L, et al
    Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
    PLoS One. 2023;18:e0290507.
    PubMed         Abstract available

  56. NOR S, Chan KG, Rahman HA, H Abdul-Mumin K, et al
    Patient satisfaction of breast reconstructive surgery following mastectomy in Brunei.
    PLoS One. 2023;18:e0289955.
    PubMed         Abstract available

  57. GONG M, Shen F, Li Y, Ming L, et al
    MLK4 as an immune marker and its correlation with immune infiltration in Cervical squamous cell carcinoma and endocervical adenocarcinoma(CESC).
    PLoS One. 2023;18:e0290462.
    PubMed         Abstract available

    Radiother Oncol

  58. SALVESTRINI V, Kim K, Caini S, Alkner S, et al
    Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
    Radiother Oncol. 2023;186:109805.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.